公开(公告)号：US20190183955A1

公开(公告)日：2019-06-20

申请号：US16169599

申请日：2018-10-24

申请人： BRIANT BURKE

发明人： BRIANT BURKE

IPC分类号： A61K36/61 ,  A61K47/10 ,  A61K47/20 ,  A61K47/22 ,  A61K9/00 ,  A61P29/00 ,  A61P19/04

CPC分类号： A61K36/61 ,  A61K9/0014 ,  A61K47/10 ,  A61K47/20 ,  A61K47/22 ,  A61P19/04 ,  A61P29/00

摘要： A topical, non-prescription formulation of essential oils combined with skin permeation enhancers for the clinical treatment of plantar fasciitis in humans. The formulation may exclude black pepper essential oil. The present compositions and methods relate to a method for treating a disorder chosen from plantar fasciitis, bursitis, or arthritis in humans in a patient in need thereof, comprising administering to the patient compositions having a therapeutically effective amount of a combination of isoprenoidal essential oils, for example, Tea Tree Oil and Clove Bud Oil, in combination with a skin permeation enhancer, such as DMSO, the administration comprising contacting an affected area of skin of the patient with the composition.

公开(公告)号：US20190144856A1

公开(公告)日：2019-05-16

申请号：US15543816

申请日：2016-01-15

申请人： University of Lowa Research Foundation

发明人： Liu HONG ,  Brad A. AMENDT ,  Aliasger K. SALEM ,  Satheesh ELANGOVAN ,  Gustavo Avila Ortiz ,  Thad SHARP

IPC分类号： C12N15/113 ,  A61P19/04 ,  A61P19/02 ,  A61K47/14 ,  A61K47/18 ,  A61K47/34

CPC分类号： C12N15/113 ,  A61K47/14 ,  A61K47/18 ,  A61K47/34 ,  A61P19/02 ,  A61P19/04 ,  C12N2310/141 ,  C12N2330/10

摘要： Compositions and methods to prevent, inhibit or treat aveolar or periodontal bone loss, enhance bone regeneration, prevent, inhibit or treat peri-implantitis or periodontitis, e.g., periodontitis or peri-implantitis associated with bone loss, or to prevent, inhibit or treat osteoarthritis are provided.

公开(公告)号：US20180318300A1

公开(公告)日：2018-11-08

申请号：US15774996

申请日：2016-11-14

申请人： MingSight Pharmaceuticals, Inc.

发明人： Michael NIESMAN ,  Kai ZHANG

IPC分类号： A61K31/506 ,  A61P19/02 ,  A61P17/06 ,  A61P19/04 ,  A61P1/00 ,  A61P25/00 ,  A61P27/02 ,  A61P37/06

CPC分类号： A61K31/506 ,  A61P1/00 ,  A61P17/06 ,  A61P19/02 ,  A61P19/04 ,  A61P25/00 ,  A61P27/02 ,  A61P37/06 ,  C07D487/04

摘要： Provided herein are compositions and methods for the treatment of autoimmune and alloimmune diseases and conditions, including rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease (IBD) (e.g., Crohn's disease, ulcerative colitis), optic neuritis, Neuromyelitis Optica, Sjögren's syndrome, psoriasis, systemic scleroderma, Ankylosing Spondylitis, autoimmune hepatitis, Graft vs host disease (GvHD), and organ transplant rejection. Said compositions useful for treating autoimmune diseases comprise pyrrolo-pyrazole PKC inhibitors.

公开(公告)号：US10076511B2

公开(公告)日：2018-09-18

申请号：US15576387

申请日：2016-05-26

申请人： TREAMID GmbH

发明人： Vladimir Evgenievich Nebolsin ,  Anastasia Vladimirovna Rydlovskaya ,  Alexandr Mikhailovich Dygai ,  Tatiana Gennadievna Borovskaya ,  Evgenii Germanovich Skurikhin

IPC分类号： A61K31/417 ,  A61P19/04 ,  A61P3/08 ,  A61P31/20 ,  A61P1/18 ,  A61P15/08 ,  A61P11/00

CPC分类号： A61K31/417 ,  A61K31/16 ,  A61K31/4164 ,  A61P1/18 ,  A61P3/08 ,  A61P11/00 ,  A61P15/08 ,  A61P19/04 ,  A61P31/20

摘要： The invention relates to the field of medicine and concerns an agent that stimulates tissue regeneration and the recovery of diminished tissue and organ function. A medicinal agent for the treatment and/or prophylaxis of a pathological condition selected from the group including metabolic syndrome, impaired glucose tolerance, hepatitis, particularly chronic hepatitis and toxic hepatitis, idiopathic pulmonary fibrosis (IPF), emphysema of the lungs, chronic obstructive pulmonary disease (COPD) and cachexia, particularly as a result of impaired glucose tolerance, pulmonary fibrosis, chronic obstructive pulmonary disease, cancer and other diseases, is proposed in the form of an agent based on Treamide. The latter is a bisamide derivative of dicarboxylic acid of formula (I) or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20240277667A1

公开(公告)日：2024-08-22

申请号：US18637711

申请日：2024-04-17

申请人： Clementia Pharmaceuticals Inc.

发明人： Clarissa DESJARDINS ,  Donna Roy GROGAN ,  Jeffrey Neal PACKMAN ,  Mark HARNETT

IPC分类号： A61K31/415 ,  A61K9/00 ,  A61K31/00 ,  A61K45/06 ,  A61P19/04 ,  A61P19/08 ,  A61P31/00

CPC分类号： A61K31/415 ,  A61K9/0053 ,  A61K31/00 ,  A61P19/04 ,  A61P19/08 ,  A61P31/00 ,  A61K9/0014 ,  A61K45/06

摘要： The invention features dosing regimens and pharmaceutical formulations for oral administration of palovarotene. The dosing regimens can reduce heterotopic ossification, reduce the number of flare-ups, and/or reduce the severity of flare-ups in subjects suffering from fibrodysplasia ossificans progressiva.

公开(公告)号：US12054753B2

公开(公告)日：2024-08-06

申请号：US17134703

申请日：2020-12-28

申请人： Acceleron Pharma Inc.

发明人： Ravindra Kumar ,  Asya Grinberg ,  Dianne S. Sako ,  Roselyne Castonguay

IPC分类号： C12N9/12 ,  A61K38/00 ,  A61P3/04 ,  A61P19/04 ,  A61P21/00 ,  A61P25/28 ,  C07K19/00

CPC分类号： C12N9/12 ,  A61P3/04 ,  A61P19/04 ,  A61P21/00 ,  A61P25/28 ,  C07K19/00 ,  C12Y207/1103 ,  A61K38/00 ,  C07K2317/526 ,  C07K2319/00 ,  C07K2319/30 ,  C07K2319/32 ,  Y02A50/30

摘要： In certain aspects, the disclosure provides soluble heteromeric polypeptide complexes comprising an extracellular domain of an ALK4 receptor and an extracellular domain of ActRIIB. In certain aspects, such soluble ALK4:ActRIIB complexes may be used to regulate (promote or inhibit) growth of tissues or cells including, for example, muscle, bone, cartilage, fat, neural tissue, tumors, and/or cancerous cells. In certain aspects, such ALK4:ActRIIB complexes are can be used to improve muscle formation, bone formation, metabolic parameters, and disorders associated with these tissues, cellular networks, kidney, and endocrine systems.

公开(公告)号：US20240189332A1

公开(公告)日：2024-06-13

申请号：US18224387

申请日：2023-07-20

申请人： Viking Therapeutics, Inc.

发明人： Brian Lian ,  Hiroko Masamune ,  Geoffrey E. Barker

IPC分类号： A61K31/683 ,  A61K31/662 ,  A61K31/665 ,  A61P19/04

CPC分类号： A61K31/683 ,  A61K31/662 ,  A61K31/665 ,  A61P19/04

摘要： The present disclosure is directed to methods of treating fibrotic conditions by administration of TRβ agonists. The disclosure provides methods wherein the abnormal deposition of extracellular matrix components, such as collagen, keratin, or elastin, is reduced, either through interaction of TRβ agonists with TGF-β—dependent inflammatory pathways, or by other mechanisms, thereby ameliorating fibrotic symptoms.

公开(公告)号：US20240084029A1

公开(公告)日：2024-03-14

申请号：US18262172

申请日：2022-01-14

申请人： OncoResponse, Inc.

发明人： Kamal D. Puri

IPC分类号： C07K16/28 ,  A61P19/04 ,  A61P37/00

CPC分类号： C07K16/2896 ,  A61P19/04 ,  A61P37/00 ,  C07K2317/24

摘要： Provided herein are antibodies and methods of use thereof. The antibodies as disclosed herein bind to CD163+ on cells, such as on macrophages. These antibodies can be used in methods of treatment, such as methods of treating fibrosis.

公开(公告)号：US20230398156A1

公开(公告)日：2023-12-14

申请号：US18034110

申请日：2021-05-18

申请人： SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION ,  ACESOSTEM BIOSTRATEGIES INC.

发明人： Hyun Chul JO ,  Ji-Hye YEA

IPC分类号： A61K35/51 ,  A61P19/04

CPC分类号： A61K35/51 ,  A61P19/04

摘要： A composition having umbilical cord-derived stem cells as an active ingredient is disclosed. The composition containing umbilical cord-derived stem cells as an active ingredient, can prevent, relieve, or treat a tendon or ligament disease by regenerating and reconstructing a damaged tendon without side effects when applied for a tendon disease.

公开(公告)号：US20230381267A1

公开(公告)日：2023-11-30

申请号：US18027340

申请日：2021-09-29

申请人： Baylor College of Medicine

发明人： Brendan Lee

IPC分类号： A61K38/095 ,  A61P19/04

CPC分类号： A61K38/095 ,  A61P19/04

摘要： Embodiments of the present disclosure concern the treatment and/or prevention of Ehlers-Danlos Syndrome (EDS) or its manifestations using therapeutic compositions, such as oxytocin and/or oxytocin analogues. The therapeutic compositions may decrease symptoms and/or reverse disease progression.